{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:15:35Z","timestamp":1792732535944,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,1]],"date-time":"2027-08-01T00:00:00Z","timestamp":1817078400000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:38:39Z","timestamp":1779899919000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Asmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustaqeem","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.05.004_bib0001","doi-asserted-by":"crossref","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","article-title":"NCCN guidelines(R) insights: multiple myeloma, version 1.2025","volume":"23","author":"Kumar","year":"2025","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.004_bib0003","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Kumar","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","article-title":"Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-018-0106-3","article-title":"Phase 1\/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma","volume":"8","author":"Kumar","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2026.05.004_bib0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.15679","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s13063-020-04739-8","volume":"21","author":"Hinsley","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.clml.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-022-00626-4","article-title":"Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results","volume":"12","author":"Auner","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1002\/cam4.5422","article-title":"Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/oncolo\/oyad017","article-title":"Ixazomib, oral metronomic cyclophosphamide, and dexamethasone for first-line treatment of multiple myeloma: a phase II Brown University Oncology Group study","volume":"28","author":"Pelcovits","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2026.05.004_bib0015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/bjh.19626","article-title":"An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome","volume":"205","author":"He","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1038\/s41598-025-91126-5","article-title":"Ixazomib or lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1007\/s00277-025-06441-8","article-title":"Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature","volume":"104","author":"L\u00f6ffler","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12185-025-03927-z","article-title":"Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed\/refractory multiple myeloma","volume":"121","author":"Ng","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosinol","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.clml.2025.06.006","article-title":"Real-world comparison of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in patients with relapsed\/refractory multiple myeloma: KMM2004 study","volume":"25","author":"Kim","year":"2025","journal-title":"Clin Lymph Myeloma Leukemia"},{"key":"10.1016\/j.clml.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-025-01411-9","article-title":"Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma","volume":"16","author":"Dimopoulos","year":"2026","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:20:39Z","timestamp":1785702039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001497"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}